Skip to content

A randomized, double-blind, controlled study on the treatment of stable vitiligo with compound Honghuabuji granules

A randomized, double-blind, controlled study on the treatment of stable vitiligo with compound Honghuabuji granules

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046436
Enrollment
Unknown
Registered
2021-05-15
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo

Interventions

Sponsors

Shanghai Dermatology Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients who are clearly diagnosed as vitiligo, and those who have been diagnosed as blood stasis syndrome by Chinese medicine; 2. Patients aged 18 to 60 years; 3. Mainly confined and sporadic; 4. In order to accurately compare the test results, the hypopigmented area of all patients in this test is <= 10% of the total body surface area; 5. No systemic or topical glucocorticoid or immunosuppressant treatment or withdrawal of the drug for more than 3 months within 3 months; 6. Patients with leukoplakia that have not expanded within 6 months and are in a stable phase; 7. Patients who agree to take pictures of the skin lesions and can complete the treatment and follow-up on time.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. System or topical vitiligo drug treatment within 3 months; 3. Patients who are allergic to tacrolimus ointment and compound Honghuabuji granules. 4. Patients with severe heart, liver, kidney and other system diseases; 5. Patients who withdraw halfway and have incomplete information.

Design outcomes

Primary

MeasureTime frame
White spot area;

Secondary

MeasureTime frame
Vitiligo impact scale-22;TCM symptoms scale;

Countries

China

Contacts

Public ContactZheng Qi

Shanghai Dermatology Hospital

drzheng0@163.com+86 18217188137

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026